Andrew P. Han
Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.
The program will provide funding and expertise to clinics in low-income countries to run methylation array-based assays to classify central nervous system tumors in children.
SomaLogic Cofounder and former CEO Larry Gold and Chief Technology Officer Jason Cleveland have filed a class action suit, accusing the board of breach of fiduciary duty.
The sequencing instrument maker said it plans to finalize terms for a sale or IPO by the end of the second quarter of 2024.
While AMP asked members to register their opposition officially, one official said "there probably will be a lawsuit."
A comparison for 144 solid tumor samples showed a "high degree of alignment" with FoundationOne CDx and better calling of CNAs than Illumina's TSO 500.
The so-called "five-base" assay, which includes methylation calls thanks to PacBio's Revio instrument, will be evaluated as a frontline test for critically ill newborns.
Illumina will be able to choose the method of divestment, but may need to provide Grail with more than $1 billion in cash to fund operations for several years.
The firms' merger agreement, filed with the US Securities and Exchange Commission, contradicts previous messaging on layoffs at Standard BioTools.
In addition to proving clinical utility, the startup will have to navigate issues of regulatory strategy, sequencing technology, and additional indications.
The EC also fined Grail €1,000, a symbolic amount and the first instance of imposing a fine on a company that was the target of a prematurely closed acquisition.